Erectile function changes after coronary stent procedures for heart attack versus stable angina
Erectile Function After Percutaneous Coronary Intervention in Myocardial Infarction and Non-Infarction Patients: A Prospective Comparative Study.
We will see if erectile function gets better or worse over 3 and 6 months in men who had a successful PCI (stent procedure) for a heart attack or for stable angina.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 30 Years to 75 Years |
| Sex | Male |
| Sponsor | Kırıkkale University Academic / other |
| Locations | 1 site (Kirikkale) |
| Trial ID | NCT07444697 on ClinicalTrials.gov |
What this trial studies
This is an observational follow-up of men aged 30–75 who undergo successful percutaneous coronary intervention for either acute myocardial infarction or stable angina, with groups compared head-to-head. Erectile function is measured using the International Index of Erectile Function (IIEF) at baseline (post-recovery), 3 months, and 6 months, alongside Beck Depression Inventory and Fear of Cardiac Recurrence and Progression questionnaires. The study excludes patients with malignancy, major neurological causes of ED, uncontrolled diabetes (HbA1c >9%), more than two chronic systemic diseases, or chronic polypharmacy, and conducts face-to-face follow-up visits at the treating hospital. The primary aim is to test whether baseline erectile status predicts subsequent cardiac events and the secondary aim is to see whether having had a myocardial infarction versus stable angina changes erectile outcomes over time.
Who should consider this trial
Good fit: Men aged 30–75 who are sexually active, hemodynamically stable after a successful PCI for either acute myocardial infarction or stable angina, survived the index hospitalization, and can attend in-person follow-up visits and give consent.
Not a fit: Men with active malignancy, major neurologic causes of erectile dysfunction, uncontrolled diabetes, multiple severe comorbidities, chronic polypharmacy, or no recent sexual activity are unlikely to benefit from this study's findings.
Why it matters
Potential benefit: If findings show clear links, results could help clinicians counsel men about sexual function after PCI and identify patients at higher cardiac risk.
How similar studies have performed: Previous observational studies have linked coronary artery disease and erectile dysfunction and some reports suggest revascularization can improve sexual function, but direct comparisons of post-PCI outcomes after heart attack versus stable angina are limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria * Male patients aged 30-75 years * Undergoing successful percutaneous coronary intervention (PCI) for one of the following: * Acute myocardial infarction (Group 1) * Stable angina (Group 2) * Hemodynamically stable after the PCI procedure * Survival of the index hospitalization * Ability to provide written informed consent * Sexually active within the 3 months prior to enrollment * Willingness and ability to complete follow-up visits and questionnaires at: * Baseline (post-PCI recovery) * 3 months * 6 months Exclusion Criteria * Known malignancy (active or recently treated) * Neurological disorders affecting erectile function, including: * Spinal cord injury * Multiple sclerosis * Parkinson's disease * Uncontrolled diabetes mellitus (HbA1c \> 9%) * Presence of more than two chronic systemic diseases, such as: * Severe renal disease * Severe hepatic disease * Severe pulmonary disease * Polypharmacy, defined as chronic use of more than three daily medications * Absence of sexual activity or lack of a sexual partner * Refusal or inability to provide informed consent or complete study questionnaires * Severe psychiatric illness interfering with study participation * Endocrine disorders, including: * Untreated hypogonadism * Thyroid disease * Major post-PCI complications preventing participation, including: * Reinfarction * Stroke * Heart failure
Where this trial is running
Kirikkale
- The Hospital of Kirikkale Univerity Faculty of Medicine — Kirikkale, Turkey (Türkiye) (Recruiting)
Study contacts
- Principal investigator: Timucin Sipal, Assistan Prof — Kirikkale Univerity faculty of medicine department of Urology
- Study coordinator: Timucin Sipal, MD, PhD
- Email: drtimucin@hotmail.com
- Phone: +905338170659
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.